Brief: Algernon Neuroscience Provides Update On Phase 1 Dmt Clinical Study, Drug Found Safe To Proceed To Next Phase
16/02/2023 12:26
Feb 16 (Reuters) - Algernon Pharmaceuticals Inc
AGN.CD :
* ALGERNON NEUROSCIENCE PROVIDES UPDATE ON PHASE 1 DMT
CLINICAL
STUDY, DRUG FOUND SAFE TO PROCEED TO NEXT PHASE
Source text for Eikon: ID:nGNX3scdc9
Further company coverage: AGN.CD
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Grey Matters Health
See all newsBrief: Grey Matters Announces The Closing Of Its Equity And Convertible Debenture Private Placement Totalling CAD $1.12 Million
Brief: Algernon Announces Additional Increase To Private Placement Financing
Brief: Algernon Health Announces Private Placement
Brief: Algernon Announces Closing Of The Private Placement Financing
Brief: Algernon Announces $1 Mln Private Placement